2018-11-15T10:40:14-06:00 2017-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1400 BELLEVUE WA 98004 990 2017-01-01 352577906 MAXAID MAXA 4257788660 200 NE PACIFIC STREET NO 103 SEATTLE WA 98105 PATRICIA M PEARCE CFO & VP, ADMINISTRATION 4257788660 2018-11-13 1 JANE M SEARING P00000565 4254544919 2018-11-13 65.158.230.194 2018-11-13 12:37:11 PS P 2DE068ACBFA10A31F139242116409E8904B6E6F4 850A304DB8663794F051F0469C279D0BE1EBB04F 2017 2018-06-14 16:35:46Z PATRICIA M PEARCE 200 NE PACIFIC STREET NO 103 SEATTLE WA 98105 177671918 0 X WWW.MAXAID.ORG X 2016 WA MAXAID IS A 501(C)(3) NON-PROFIT THAT WAS SET UP BY THE MAX FOUNDATION AS A SUBSIDIARY TO SUPPORT ITS MISSION OF INCREASING GLOBAL ACCESS TO TREATMENT, CARE, AND SUPPORT FOR PEOPLE LIVING WITH CANCER. 7 6 0 6 0 0 0 177650543 0 0 0 0 0 21375 0 177671918 0 36413085 0 0 0 0 0 0 0 0 2897324 0 39310409 0 138361509 0 139136934 0 775425 0 138361509 X MAXAID IS A 501(C)(3) NON-PROFIT THAT WAS SET UP BY THE MAX FOUNDATION AS A SUBSIDIARY TO SUPPORT ITS MISSION OF INCREASING GLOBAL ACCESS TO TREATMENT, CARE, AND SUPPORT FOR PEOPLE LIVING WITH CANCER. THE PRIMARY PURPOSE OF MAXAID IS TO CARRY OUT TREATMENT ACCESS SOLUTIONS FOR ONCOLOGY PRODUCTS IN LOW-AND-MIDDLE INCOME COUNTRIES IN PARTNERSHIP WITH THE MAX FOUNDATION. 0 0 39308941 36413085 21375 FROM ITS LAUNCH, MAXAID HAS HOSTED THE MAX FOUNDATION'S COLLABORATION WITH NOVARTIS, A LEADING GLOBAL HEALTHCARE COMPANY, AROUND HUMANITARIAN ACCESS TO THEIR MEDICINES GLIVEC AND TASIGNA IN A JOINT INITIATIVE KNOWN AS CMLPATH TO CARE. IN 2017, THE COLLABORATION ENABLED THOUSANDS OF PATIENTS IN LOW AND MIDDLE INCOME COUNTRIES TO ACCESS MUCH NEEDED ONCOLOGY PRODUCTS THAT THEY WOULD NOT HAVE OTHERWISE BEEN ABLE TO ACCESS. ACCESS TO MEDICINES WAS ENABLED THROUGH THE MAX FOUNDATION'S PATIENT-CENTERED TREATMENT ACCESS MODEL KNOWN AS MAX ACCESS SOLUTIONS. IN THE CASE OF MAXAID, ONCOLOGY PRODUCTS WERE RECEIVED FROM THE DRUG MANUFACTURER NOVARTIS AND CHANNELED TO INIDVIDUAL PATIENTS VIA THE MAX FOUNDATION'S NETWORK OF HEALTHCARE PROVIDERS AND TREATMENT CENTERS. 39308941 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 7 6 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 X PATRICIA GARCIA-GONZALEZ 4257788660 200 NE PACIFIC STREET SUITE 103 SEATTLE WA 98105 PATRICIA GARCIA-GONZALEZ CEO 1.00 50.00 X X 0 203520 15352 PAULA BOULTBEE PRESIDENT 1.00 4.00 X X 0 0 0 ROBERT FARMER DIRECTOR 0.50 2.00 X 0 0 0 DAVID TINGSTAD SECRETARY 1.00 2.00 X X 0 0 0 TRACEY HIGGINS DIRECTOR 0.50 2.00 X 0 0 0 JERRY SCOTT TREASURER 1.00 2.00 X X 0 0 0 GRANT RUBENSTEIN DIRECTOR 0.50 2.00 X 0 0 0 0 203520 15352 0 0 1 0 TANNER PHARMA CH GMBH ALTE STEINHAUSERSTRASSE 21 CHAM SZ 6330 PROFESSIONAL SERVICES 1689256 THE MAX FOUNDATION 200 NE PACIFIC STREET SUITE 103 SEATTLE WA 98105 PROFESSIONAL SERVICES 1200000 2 177650543 174776993 177650543 REIMBURSABLE FEES 900099 21375 21375 21375 177671918 21375 0 0 36413085 36413085 2895856 2895856 1468 1468 39310409 39308941 1468 0 0 644577 0 138492297 0 60 0 139136934 0 124697 0 650728 0 775425 X 0 138361509 0 138361509 0 139136934 138361509 0 X 0 1 X 1 0 X X X 1 THE MAX FOUNDATION 911893957 7 1 1200000 36413085 1 1200000 36413085 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 DUE TO MAX FOUNDATION 650728 650728 1 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTS TO RECIPIENTS IN REGION 524588 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS IN REGION 2909770 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS IN REGION 4498260 RUSSIA AND THE NEWLY INDEPENDENT STATES 0 0 GRANTS TO RECIPIENTS IN REGION 5374059 SOUTH AMERICA 0 0 GRANTS TO RECIPIENTS IN REGION 1053737 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS IN REGION 6651306 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS IN REGION 15272976 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 FUNDRAISING 0 0 0 0 0 0 36284696 0 36284696 0 0 DRUG CENTRAL AMERICA & THE CARIBBEAN 155 524588 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG EAST ASIA & THE PACIFIC 530 2909770 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG NORTH AMERICA 751 4498260 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG RUSSIA AND THE NEWLY INDEPENDENT STATES 2544 5374059 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH AMERICA 300 1053737 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH ASIA 1286 6651306 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SUB-SAHARAN AFRICA 4936 15272976 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE 1 0 0 0 0 0 PART I, LINE 2: ALL GRANTS TO FOREIGN ENTITIES OR INDIVIDUALS ARE MADE SUBJECT TO A WRITTEN AGREEMENT OR AWARD LETTER THAT CLEARLY DEFINES DELIVERABLES. THE MAX FOUNDATION MAINTAINS A PROGRAM DATABASE IN ORDER TO TRACK DOCUMENTATION OF GRANT REQUESTS, QUALIFIED GRANTEES, AND FULFILMENT OF GRANT REQUESTS. PROGRAM STAFF MEMBERS MONITOR THE EXECUTION OF GRANT DELIVERABLES TO ENSURE THAT THE TERMS OF THE AGREEMENT ARE FULFILLED ON A TIMELY BASIS. PART I, LINE 3: THE EXPENDITURES REPORTED ON SCHEDULE F, PART I, LINE 3 ARE ON THE ACCRUAL BASIS OF ACCOUNTING. PART IV, LINE 1: FORM 926 IS NOT REQUIRED TO BE FILED BECAUSE THE TRANSFER TO A FOREIGN CORPORATION DOES NOT MEET THE REPORTING REQUIREMENTS IN IRC SEC. 6038(A)(1)(A). 0 0 0 0 0 0 0 0 0 PATRICIA GARCIA-GONZALEZ CEO 0 193520 0 10000 0 0 0 0 0 15352 0 218872 0 0 PART I, LINE 3 NO REVIEW OF COMPENSATION WAS REQUIRED SINCE NO OFFICERS WERE PAID BY THIS ORGANIZATION. A RELATED AND SUPPORTED ORGANIZATION, THE MAX FOUNDATION, PERFORMS THE ANNUAL REVIEW PROCESS FOR THESE INDIVIDUALS AS APPLICABLE. X 12490686 174776993 COMM VOL AVG WHOLESALE 0 0 1 0 PART I, COLUMN (B): THE NUMBER IN COLUMN B REPRESENTS THE NUMBER OF TABS CONTRIBUTED. FORM 990, PART I, LINE 6, VOLUNTEERS: THERE ARE SIX VOLUNTEER BOARD MEMBERS. FORM 990, PART VI, SECTION A, LINE 8B DUE TO THE SIZE OF THE ORGANIZATION, COMMITTEES ARE NOT DEEMED NECESSARY BY THE MAXAID BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B THE TAX RETURN IS PREPARED BY AN OUTSIDE ACCOUNTANT. AFTER PREPARATION, THE FINANCE COMMITTEE PERFORMS A REVIEW OF THE RETURN. THE RETURN IS THEN FILED WITH THE IRS. A COPY IS PROVIDED TO THE BOARD OF DIRECTORS PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 15 NO REVIEW OF COMPENSATION WAS REQUIRED SINCE NO OFFICERS WERE PAID BY THIS ORGANIZATION. A RELATED AND SUPPORTED ORGANIZATION, THE MAX FOUNDATION, PERFORMS THE ANNUAL REVIEW PROCESS FOR THESE INDIVIDUALS AS APPLICABLE. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE PROVIDED UPON REQUEST. FORM 990, PART VI, LINES 12, 13 AND 14: MAXAID FOLLOWS THE CONFLICT OF INTEREST, DOCUMENT RETENTION AND WHISTLEBLOWER POLICIES OF ITS SUPPORTED ORGANIZATION, THE MAX FOUNDATION. THE MAX FOUNDATION 200 NE PACIFIC STREET SUITE 103 SEATTLE WA 98105 911893957 EXPAND HUMANITARIAN ACCESS TO TREATMENTS FOR CANCER WA 501(C)(3) LINE 10 0 THE MAX FOUNDATION SOUTH AFRICA TRUST 10 COSMOSPLACE DOORNPOORT PRETORIA SF TO SUPPORT THE MAX FOUNDATION SF MAX FOUNDATION T 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0